[en] Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, the limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluate SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naive or previously infected volunteers. By 21 days after receiving the first dose of the vaccine, 94% of naive participants develop spike-specific IgG antibodies. A single Sputnik V dose elicits higher antibody levels and virus-neutralizing capacity in previously infected individuals than in naive ones receiving the full two-dose schedule. The high seroconversion rate after a single dose in naive participants suggests a benefit of delaying administration of the second dose to increase the number of people vaccinated. The data presented provide information for guiding public health decisions in light of the current global health emergency.
Disciplines :
Immunology & infectious disease
Author, co-author :
Rossi, Andres H ; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Ojeda, Diego S ; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Varese, Augusto; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
Sanchez, Lautaro ; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Gonzalez Lopez Ledesma, Maria M; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Mazzitelli, Ignacio ; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
Alvarez Juliá, Anabel; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Oviedo Rouco, Santiago; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Pallarés, Horacio M; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Costa Navarro, Guadalupe S; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Rasetto, Natali Belen ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques ; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Garcia, Corina I; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Wenker, Shirley D ; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Ramis, Lila Y; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Bialer, Magalí G; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
de Leone, Maria Jose; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Hernando, C Esteban; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Sosa, Santiago ; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Bianchimano, Luciana; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Rios, Antonella S; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Treffinger Cienfuegos, Maria Soledad; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Caramelo, Julio J; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Longueira, Yesica; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina ; Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Caba, Argentina
Laufer, Natalia; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina ; Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Caba, Argentina
Alvarez, Diego E; Instituto de Investigaciones Biotecnológicas, Univ. Nacional de San Martín-CONICET, Buenos Aires, Argentina
Carradori, Jorge; Laboratorio Lemos S.R.L., Buenos Aires, Argentina
Pedrozza, Dariana; Hospital Interzonal General de Agudos Dr Pedro Fiorito, Provincia de Buenos Aires, Argentina
Rima, Alejandra; Hospital Interzonal General de Agudos Evita, Provincia de Buenos Aires, Argentina
Echegoyen, Cecilia; Hospital Interzonal General de Agudos Prof. Dr. Rodolfo Rossi, Provincia de Buenos Aires, Argentina
Ercole, Regina; Hospital Interzonal Especializado de Agudos y Crónicos San Juan de Dios, Provincia de Buenos Aires, Argentina
Gelpi, Paula; Hospital Interzonal General de Agudos San Roque, Provincia de Buenos Aires, Argentina
Marchetti, Susana; Hospital Interzonal General de Agudos San Martín, Provincia de Buenos Aires, Argentina
Zubieta, Martín; Hospital de Alta Complejidad El Cruce "Nestor Kirchner," Provincia de Buenos Aires, Argentina
Docena, Guillermo; Instituto de Estudios Inmunológicos y Fisiopatológicos, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, CONICET-CIC, La Plata, Argentina
Kreplak, Nicolas; Ministerio de Salud de Provincia de Buenos Aires, Argentina
Yanovsky, Marcelo; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Geffner, Jorge; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
Pifano, Marina; Ministerio de Salud de Provincia de Buenos Aires, Argentina
Gamarnik, Andrea V ; Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina
Fundación Williams Ministry of Science Technology and Productive Innovation NIAID - National Institute of Allergy and Infectious Diseases NIH - National Institutes of Health
Funding text :
The authors are grateful to the Sean Whelan laboratory for providing the VSV-eGFP-SARS-CoV-2 pseudovirus and advice on neutralization assays and Dr. Ana Fernandez Sesma for helpful discussions. This work was supported by NIH (NIAID) R01.AI095175 , PICT-2017-1717 , and PICT-2015-2555 (to A.V.G.) and by Fundación Williams and the National Ministry of Science, Technology, and Innovation of Argentina . We are grateful to the following institutions and staff who contributed to the sample collection: Biobanco de Enfermedades Infecciosas: Alejandro Czernikier, Yanina Ghiglione, Denise Giannone, María L. Polo, Florencia Quiroga, Gabriela Turk, and Belen Vecchione; HIEAC “San Juan de Dios”: Andrea Gatelli, Sofia Di Bella, Agustina Martinez, Martina Ferioli, Francisco Echeverria, Ramiro Agüero, Ana Caproli, and Karina Gil; HIGA “Dr. Rodolfo Rossi”: Claudia Varela, Ángeles Baridon, Soledad Ocampo, Emanuel Zapata, Melina Cancela, and Verónica Forneris; HIGA “San Martín”: Sebastián Gutiérrez, María Maxwell, Rosario Marcó, Cecilia Zolorzano, Micaela Nieva, and Claudia Conta; HIGA “Evita”: Silvina Olivera, Isabel Desimone, and Alejandra Musto; HIGA “Dr. Pedro Fiorito”: Aime Balanzino, Katherina Prost, Miriam Pereiro, Eliana Correa, Noelia Portillo, Cynthia Leguizamon, and Alicia Quetglas; HIGA “San Roque”: Mariana Artazcoz, Agustina Venturi Grossi, Rosana Toro, Anabella Masci, and Sofía Padín; HAC “El Cruce- Néstor Kirchner”: Mabel Skrypnik, Blanca Guevara, Virginia Aniasi, and Alan Estigarribia.The authors are grateful to the Sean Whelan laboratory for providing the VSV-eGFP-SARS-CoV-2 pseudovirus and advice on neutralization assays and Dr. Ana Fernandez Sesma for helpful discussions. This work was supported by NIH (NIAID) R01.AI095175, PICT-2017-1717, and PICT-2015-2555 (to A.V.G.) and by Fundación Williams and the National Ministry of Science, Technology, and Innovation of Argentina. We are grateful to the following institutions and staff who contributed to the sample collection: Biobanco de Enfermedades Infecciosas: Alejandro Czernikier, Yanina Ghiglione, Denise Giannone, María L. Polo, Florencia Quiroga, Gabriela Turk, and Belen Vecchione; HIEAC “San Juan de Dios”: Andrea Gatelli, Sofia Di Bella, Agustina Martinez, Martina Ferioli, Francisco Echeverria, Ramiro Agüero, Ana Caproli, and Karina Gil; HIGA “Dr. Rodolfo Rossi”: Claudia Varela, Ángeles Baridon, Soledad Ocampo, Emanuel Zapata, Melina Cancela, and Verónica Forneris; HIGA “San Martín”: Sebastián Gutiérrez, María Maxwell, Rosario Marcó, Cecilia Zolorzano, Micaela Nieva, and Claudia Conta; HIGA “Evita”: Silvina Olivera, Isabel Desimone, and Alejandra Musto; HIGA “Dr. Pedro Fiorito”: Aime Balanzino, Katherina Prost, Miriam Pereiro, Eliana Correa, Noelia Portillo, Cynthia Leguizamon, and Alicia Quetglas; HIGA “San Roque”: Mariana Artazcoz, Agustina Venturi Grossi, Rosana Toro, Anabella Masci, and Sofía Padín; HAC “El Cruce- Néstor Kirchner”: Mabel Skrypnik, Blanca Guevara, Virginia Aniasi, and Alan Estigarribia. Conceptualization, A.H.R. J.G. G.D. M.P. N.K. and A.V.G.; general coordination, M.P. A.H.R. A.A.J. and A.V.G.; collection of serum samples and clinical data, D.P. A. Rima, C.E. R.E. P.G. S.M. M.Z. Y.L. and N.L.; production of SARS-CoV-2 antibody ELISA (IgG) Kit (COVIDAR), D.S.O. L.S. M.M.G.L.L. H.M.P. G.S.C.N. D.A. J.J.C. and J.C.; IgG anti-spike titer determination, D.S.O. L.S. N.R. C.I.G. S.D.W. L.Y.R. M.G.B. M.J.d.L. C.E.H. S.S. L.B. A. Ríos, M.S.T.C. Y.L. and N.L.; determination of neutralizing titers using WT SARS-CoV-2 virus, A.V. I.M. and J.G.; determination of neutralizing titers using CoV2pp GFP pseudotyped virus, D.S.O. L.S. M.M.G.L.L. D.A. and S.O.R.; data curation and analysis, D.S.O. L.S. S.O.R. J.J.C. M.Y. and A.V.G.; writing – original draft, M.M.G.L.L. D.S.O. L.S. S.O.R. M.Y. and A.V.G.; funding acquisition, A.V.G. The authors declare no competing interests. One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. We worked to ensure gender balance in the recruitment of human subjects. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list.
Logunov, D.Y., Dolzhikova, I.V., Zubkova, O.V., Tukhvatulin, A.I., Shcheblyakov, D.V., Dzharullaeva, A.S., Grousova, D.M., Erokhova, A.S., Kovyrshina, A.V., Botikov, A.G., et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396 (2020), 887–897.
Logunov, D.Y., Dolzhikova, I.V., Shcheblyakov, D.V., Tukhvatulin, A.I., Zubkova, O.V., Dzharullaeva, A.S., Kovyrshina, A.V., Lubenets, N.L., Grousova, D.M., Erokhova, A.S., et al., Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397 (2021), 671–681.
Hung, I.F.N., Poland, G.A., Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet 397 (2021), 854–855.
Krammer, F., Srivastava, K., Alshammary, H., Amoako, A.A., Awawda, M.H., Beach, K.F., Bermúdez-González, M.C., Bielak, D.A., Carreño, J.M., Chernet, R.L., et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N. Engl. J. Med. N. Engl. J. Med. 384 (2021), 1372–1374.
Ebinger, J.E., Fert-Bober, J., Printsev, I., Wu, M., Sun, N., Prostko, J.C., Frias, E.C., Stewart, J.L., Van Eyk, J.E., Braun, J.G., et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 27 (2021), 981–984.
Ojeda, D.S., Gonzalez Lopez Ledesma, M.M., Pallarés, H.M., Costa Navarro, G.S., Sanchez, L., Perazzi, B., Villordo, S.M., Alvarez, D.E., Echavarria, M., Oguntuyo, K.Y., et al., BioBanco Working Group. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog., 17, 2021, e1009161.
Kristiansen, P.A., Page, M., Bernasconi, V., Mattiuzzo, G., Dull, P., Makar, K., Plotkin, S., Knezevic, I., WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet 397 (2021), 1347–1348.
Case, J.B., Rothlauf, P.W., Chen, R.E., Liu, Z., Zhao, H., Kim, A.S., Bloyet, L.M., Zeng, Q., Tahan, S., Droit, L., et al. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host Microbe 28 (2020), 475–485.e5.
